CFDE Data Portal | Search PIN1-DT

	Label	Description
	PIN1-DT Gene (Entity type)	ENSG00000267289 - PIN1 divergent transcript
	GSE239844 crizotinib 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE193351 ruxolitinib 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 trametinib NF1 8 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE200982 PLAC8 knockout 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE199107 tryptophan 6 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE101239 5 V 6 VALPROIC ACID MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS

PIN1-DT

ENSG00000267289 - PIN1 divergent transcript

GSE239844 crizotinib 6 v 9 human up

A Gene Set from LINCS

GSE193351 ruxolitinib 1 v 2 human dn

A Gene Set from LINCS

GSE213588 trametinib NF1 8 v 11 human up

A Gene Set from LINCS

GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP

A Gene Set from LINCS

GSE200982 PLAC8 knockout 0 v 2 human dn

A Gene Set from LINCS

GSE199107 tryptophan 6 v 7 human up

A Gene Set from LINCS

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE101239 5 V 6 VALPROIC ACID MOUSE UP

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.